In the UK around 60,000 babies are born prematurely each year. Preterm birth is the leading cause of morbidity and mortality in neonates, and optimal nutrition plays a critical role in their survival.
The World Health Organisation recommends that VLBW infants who fail to gain weight despite adequate breastfeeding should be given human milk fortifiers, preferably those which are human milk based.
With an extensive background in human milk technology, NeoKare Nutrition Ltd manufactures quality human milk products for the unique nutritional needs of premature and low-birth-weight babies.
Having pioneered the proprietary breast milk technology at the King Edward Memorial Hospital, Perth, Western Australia in 2001, we also have the experience of establishing a successful mother’s milk processing site in India, which remains the first and only such site in Asia.
Over the last 5 years, our sister company, NeoLacta Lifesciences has supplied screened, pasteurised 100% Human milk-based products to over 20,000 babies. NeoLacta Lifesciences is the only ISO 22000:2018, HACCP and GMP certified facility in India and Asia, which processes human milk with proprietary technology in-line with Human Milk Banking guidelines. NeoLacta’s products are available at more than 200 tertiary care centres helping clinicians access 100% human milk-based nutritional solutions for the most vulnerable premature and high-risk infants.
NeoKare has established the first and only pharmaceutical grade manufacturing facility for the testing and processing of human milk in Europe. Based in Worcestershire, UK, the facility is fully compliant with all relevant standards and guidelines of the Food Standards Authority.
Our processing facility consists of multiple HEPA-filtered ISO7 cleanrooms and food safety is ensured through a HACCP management system from milk collection through to the distribution of finished product.